Baker Hughes & C3 AI Release BHC3 Production Schedule Optimization Application for Demand Planning & Manufacturing Production Scheduling
3.3.2021 17:00:00 EET | Business Wire | Press release
Baker Hughes (NYSE: BKR) and C3 AI (NYSE: AI) have announced the launch of BHC3™ Production Schedule Optimization (PSO), an enterprise AI application for industrial demand planning and manufacturing production scheduling. The application improves supply chain and delivery performance for highly engineered products while minimizing manufacturing costs by generating industrial customer demand predictions and optimal production schedules using a holistic view of buyer activity, supply chain materials, and manufacturing and distribution operations.
BHC3 PSO produces accurate demand forecasts for industrial and oil and gas operations as well as defined manufacturing and distribution schedules, factoring in dynamic market conditions, operational constraints, and the inherent uncertainty associated with these operations. BHC3 PSO also generates actionable insights for buyers, sellers, inventory analysts and production schedulers to make near real-time adjustments to production schedules for industrial and oil and gas operations. The application is now generally available to oil and gas and manufacturing businesses globally and is the latest addition to the growing portfolio of BHC3 artificial intelligence (AI) applications from the BakerHughesC3.ai alliance.
BHC3 PSO integrates a wide range of inputs, including feedstock availability, changing market prices, priority customer orders, increasing reworks, and unplanned downtime. With the application, users can optimize goals across manufacturing and distribution activities, including inventory minimization and throughput maximization, while considering operational constraints including storage policy, asset performance, and resource availability.
BHC3 PSO has already demonstrated success with trial customers. For example, a large hydrocarbon processing company that configured the BHC3 PSO application for a polypropylene plant was able to optimize production schedules and reduce manufacturing costs. After a 16-week trial, the company achieved a 20% improvement in demand forecasting accuracy by generating optimal production schedules without manual adjustment and adopting machine learning models.
“We are committed to leading and advancing the digital transformation of energy operations globally. This application is the latest in a series of new AI solutions we have launched in recent months that allow customers to achieve significant cost reductions, new levels of productivity, and organizational alignment for highly engineered products and industrial plants,” said Ed Abbo, C3 AI president and CTO. “BHC3 Production Schedule Optimization supports discrete, batch, semi-batch, and continuous manufacturing processes in network and multi-stage environments, delivering cost and productivity benefits across midstream and downstream oil, gas, and chemicals operations."
“Enterprise AI has the ability to create value and deliver results for manufacturing across the energy value chain,” said Uwem Ukpong, executive vice president of regions, alliances & enterprise sales at Baker Hughes. “Optimization of the supply chain and reduction of production costs are especially relevant today for energy and industrial businesses. BHC3 Production Schedule Optimization combines the manufacturing and technology expertise of Baker Hughes with C3 AI’s leading technology to help operators better forecast materials production to serve their customers.”
For more information about BHC3 product offerings, please visit BakerHughesC3.ai.
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is a leading provider of Enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
About Baker Hughes
Baker Hughes (NYSE: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and with operations in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005570/en/
Contact information
C3.ai Public Relations
Edelman
Lisa Kennedy
415-914-8336
pr@c3.ai
Investor Relations
IR@C3.ai
Baker Hughes Contacts:
Media Relations
Ashley Nelson
+1 925-316-9197
Ashley.nelson1@bakerhughes.com
Investor Relations
Jud Bailey
+1 281-809-9088
investor.relations@bakerhughes.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 20:09:00 EET | Press release
Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results while favouring its own Google Shopping product, causing sustained and quantifiable commercial damage to PriceRunner over mo
INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 17:49:00 EET | Press release
INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globally. Now, INRIX is launching a new generation of automation and intelligence to help agencies and enterprises move faster from analyzing data to making deci
Check Point and ControlPlane Partner to Help Enterprises Securely Scale AI and Accelerate Agentic Innovation24.2.2026 16:30:00 EET | Press release
ControlPlane, a specialist AI Security and DevSecOps consultancy, and Check Point Software Technologies Ltd., a pioneer and global leader in cyber security solutions, today announced a strategic collaboration to help enterprises securely adopt Large Language Models (LLMs) and agentic AI systems at scale. The partnership delivers a comprehensive, regulator-ready security framework designed to reduce risk, protect sensitive data, and enable organizations to move confidently from AI experimentation to production deployment. By combining Check Point’s AI-native threat prevention platform with ControlPlane’s deep expertise in cloud native architectures and DevSecOps, enterprises can operationalize AI securely without slowing innovation. As organizations advance AI initiatives beyond pilots, they face a growing “AI readiness gap.” Emerging threats such as prompt injection, unauthorized access, data leakage, and model misuse introduce risks that traditional security controls were not built to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom